Quick answer : Ketamine and psilocybin are both showing clinical promise for mental health conditions, but they work through different mechanisms, produce different experiences, and have very different legal statuses. Psilocybin acts on serotonin (5-HT2A) receptors, produces sessions lasting four to six hours, and remains Schedule I under federal law. Ketamine acts on the glutamate system through NMDA receptor antagonism, produces sessions of 40 to 60 minutes, and is a Schedule III controlled substance with established medical use and FDA approval.
Hardly a week goes by that I don’t hear some version of this question from a prospective patient:
“I’ve been reading about psilocybin. Should I wait for that instead of doing ketamine now?”
It’s a genuinely good question. It deserves a real answer rather than a dismissal or a sales pitch.
The short version is that these are meaningfully different treatments. They have different mechanisms, different experiences, and very different legal and access situations.
Understanding those differences can help you make a more informed decision about your own care.
Psilocybin is the psychoactive compound found in certain species of mushrooms. Your body converts psilocybin into psilocin. Psilocin acts primarily as a serotonin receptor agonist, especially at 5-HT2A receptors in the cortex.
This produces a profound change in perception, cognition, and sense of self. The effects typically last four to six hours.
Clinical research on psilocybin has generated significant interest. Researchers at Johns Hopkins, NYU, and Imperial College London have produced compelling data on psilocybin for treatment-resistant depression, major depressive disorder, and end-of-life existential distress.
Well-designed trials, particularly those involving depression, have produced notable results. As a result, the FDA granted psilocybin Breakthrough Therapy designation.
I am not going to tell you that psilocybin doesn’t work or that the science isn’t promising.
It is.
Ketamine is a dissociative anesthetic that doctors have used in clinical settings since the 1960s.
At sub-anesthetic doses, ketamine works primarily through NMDA receptor antagonism in the glutamate system. This represents a fundamentally different mechanism from psilocybin.
IV ketamine typically produces a dissociative, altered state that lasts about 40 to 60 minutes. It also promotes rapid neuroplasticity through BDNF release and synaptogenesis.
Antidepressant effects can appear within hours of the first treatment.
Federal law classifies ketamine as a Schedule III controlled substance. It remains a recognized medicine with established medical uses.
The FDA has approved Spravato (esketamine) for treatment-resistant depression and suicidal ideation. Doctors have also used ketamine therapeutically for decades in different medical settings.
Over the past 15 years, researchers have greatly expanded the evidence base for ketamine in mental health care.
Psilocybin remains a Schedule I substance under federal law. Federal law places it in the same scheduling category as heroin and does not recognize a medical use for it at the federal level.
Oregon and Colorado have created state-level licensed psilocybin therapy frameworks. California’s regulatory path for licensed psilocybin service centers remains in development.
California does not currently have a legal, licensed psilocybin therapy clinic operating in the same way as Seaside Ketamine.
Ketamine falls under Schedule III. Doctors can legally use it as a medical treatment, and patients can access ketamine treatment now.
Psilocybin: Psilocybin works primarily through the serotonin system. It acts on 5-HT2A receptors and can significantly disrupt default mode network activity. It can also produce profound changes in a person’s sense of self, sometimes called ego dissolution.
Ketamine: Ketamine works primarily through the glutamate system. It blocks NMDA receptors and promotes rapid synaptogenesis and BDNF release. It also produces dissociation, but the perceptual experience differs from that of psilocybin.
These treatments use genuinely different mechanisms. That difference may matter when clinicians consider which treatment fits a particular patient or condition.
Psilocybin: The experience typically lasts four to six hours. It can feel intense and may involve what researchers call a “challenging experience.” This can involve difficult psychological material that requires processing.
That experience can play an important role in treatment. However, it also means patients need careful preparation and a structured therapeutic setting.
Ketamine: An IV ketamine session typically lasts 40 to 60 minutes.
The shorter experience allows clinicians to titrate the dose more directly. In other words, the clinician can adjust the treatment based on the patient’s response.
Ketamine can produce a profound experience, but it generally does not last as long or feel as all-encompassing as a psilocybin experience.
Both treatments can have strong safety profiles when clinicians administer them appropriately.
Ketamine has a well-characterized safety profile from decades of medical use. At Seaside Ketamine, a physician directly supervises treatment and our team continuously monitors patients during sessions.
Clinical trials have also shown a strong safety record for psilocybin when researchers administer it in controlled settings.
Outside regulated research or state-approved programs, however, California does not currently provide the same type of legal clinical oversight for psilocybin therapy.
Psilocybin therapy: Health insurance does not currently cover psilocybin therapy. Legal therapeutic psilocybin sessions in Oregon can cost approximately $1,500 to $3,500 per session.
Ketamine (Spravato): Qualifying patients can access established insurance coverage pathways for Spravato.
IV ketamine: Insurance generally does not cover IV ketamine treatment. However, clinics can provide patients with clear treatment costs before they begin.
This is where the clinical evidence becomes especially interesting because the two treatments have different evidence profiles.
Psilocybin research has produced notable results in areas such as addiction, including tobacco and alcohol use, end-of-life existential distress, and depression.
Some research suggests that the immersive experience, ego dissolution, and mystical-type experiences associated with psilocybin may play important roles in its therapeutic effects for certain conditions.
Ketamine has strong clinical research in areas such as treatment-resistant depression, PTSD, and chronic pain. Clinicians also use it when patients need a rapid response.
Ketamine also offers ongoing treatment options, including maintenance infusions and Spravato. That availability can make ketamine more practical for some patients who need longer-term management.
Only you can answer that question.
Here is one way to think about it: if you are suffering significantly right now from a condition that ketamine has evidence for treating, waiting for psilocybin to become legally available in California may have real costs.
Those costs can include continued symptoms, continued impairment, and continued disruption to your daily life.
The consultation is free.
If we talk and ketamine does not seem like the right fit for you, I’ll tell you. If ketamine does seem appropriate, we can discuss the next steps and whether starting treatment makes sense for you now.
As of now, psilocybin remains a Schedule I controlled substance under federal law. California voters have discussed legalization but California’s regulated psilocybin therapy framework has not yet been implemented. Oregon and Colorado have moved ahead with licensed psilocybin service center frameworks, but accessing legal psilocybin therapy currently means traveling to those states. Ketamine is Schedule III — fully legal, fully regulated, and available at both our Cardiff and Newport Beach clinics today.
No, and the clinical difference matters. Psilocybin is serotonergic — it works primarily through 5-HT2A receptor agonism in the cortex, producing the perceptual and psychological effects it’s known for. Ketamine is glutamatergic — it works through NMDA receptor antagonism, promoting rapid neuroplasticity through a completely different pathway. Different mechanisms likely mean different optimal applications. This isn’t a competition between them — they’re different tools that may be best suited to different patients and different conditions.
Yes, and for some patients that might actually be a thoughtful sequence. Ketamine’s neuroplasticity-promoting effects and psilocybin’s deeper default mode network disruption may ultimately prove to be complementary rather than redundant. We don’t know yet — the research is still developing. What I’d say is: don’t let the existence of a promising future treatment prevent you from addressing your suffering with an excellent available treatment today. The two aren’t mutually exclusive.
